Sangamo Biosciences, Inc. (SGMO) uses a proprietary ZFP gene regulation technology to discover and develop a new class of therapeutic candidates for diabetic neuropathy, cardiovascular disease, cancer, and immune diseases. We are optimistic about this novel technology and are encouraged to hear that the company intends to bring more drug candidates into the clinic in 2008. We are also impressed by the company's strategy to monetize this ZFP technology.
We maintain our Buy rating on shares of Sangamo based on the platform technology and the progress the company has made for both its clinical and preclinical programs. Our target price is $18. Our Buy call is based on the progress the company has made for both its clinical and preclinical programs using its proprietary ZFP platform technology. Also the agreements with Dow AgroSciences, Genentech (DNA) and Sigma-Aldrich (SIAL) add value to the company.
Sangamo currently has three phase II trials under way and will add another phase II and two phase I trials in 2008. With total eight clinical programs and the proprietary platform technology, we believe it should be easy for the company to find partners in the coming quarters. We believe Sangamo will continue to form research and development agreements with major pharmaceutical and biotech companies to monetize its technology.
Our investment thesis relies on Sangamo's very intriguing, potentially powerful, product development technology. We use relative valuation metrics to value Sangamo shares. Sangamo has similar technology with Alnylam ({ALNY}, market cap $1.27 billion), Isis Pharma ({ISIS}, market cap $1.36 billion) and Sirna (acquired by Merck & Co, {MRK}, for $1.1 billion).
We believe Sangamo shares are undervalued compared to its peers. Our $18 target price corresponds to a market cap of $750 million for Sangamo.
Read the full analyst report on SGMO
Read the full analyst report on DNA.
Read the full analyst report on ALNY.
Read the full analyst report on ISIS.
Read the full analyst report on MRK.
Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Equity Research. See all todays Analyst Blog entries on Zacks.com.